title: ECG-triggered 18F-fluorodeoxyglucose positron emission tomography imaging of the rat heart is dramatically enhanced by acipimox.
abstract: OBJECTIVE
  18F-Fluorodeoxyglucose (FDG) imaging, provided by current positron emission tomography (PET) systems dedicated to small animals,might provide a precise functional assessment of the left ventricle (LV) in rats, although conventional metabolic conditioning by hyperinsulinaemic glucose clamping is not well adapted to this setting. This study was aimed at assessing cardiac FDG PET in rats premedicated with acipimox, a potent nicotinic acid derivative yielding comparable image quality to clamping in man.
  
  
  METHODS
  Metabolic conditioning was compared in Wistar rats between a conventional oral glucose loading (1.5 mg/kg) and acipimox, which was given at high but well tolerated doses subcutaneously (25 mg/kg) or orally (50 mg/kg). Myocardial to blood (M/B) activity ratio and myocardial signal to noise (S/N) ratio were analysed on gated FDG PET images.
  
  
  RESULTS
  The S/N ratio of the gated cardiac images evolved in parallel with the M/B activity ratio and these two ratios were independently enhanced by glucose loading and acipimox. However, these enhancements were: (1) dramatic for acipimox, especially for the high oral dose of 50 mg/kg (from 2.85 +/- 0.57 to 10.73 +/- 0.54 for the M/B ratio of rats with or without glucose loading; p<0.0001) and (2) much more limited for glucose loading (from 6.61 +/- 0.49 to 7.89 +/- 0.41 for the M/B ratio of rats with or without acipimox administration; p=0.049). With the high oral dose of acipimox, the gated cardiac FDG PET images had very high S/N ratios, at least equivalent to those currently documented in man.
  
  
  CONCLUSIONS
  Metabolic conditioning by oral doses of acipimox is highly efficient for experimental studies planned with cardiac FDG PET in rats.
authors.affiliation: Nancyclotep, Experimental Imaging Platform, Nancy, France. Sylvain.Poussier@medecine.uhp-nancy.fr
authors.forename: Sylvain
authors.initials: S
authors.lastname: Poussier
authors.forename: Fatiha
authors.initials: F
authors.lastname: Maskali
authors.forename: Nguyen
authors.initials: N
authors.lastname: Tran
authors.forename: Christophe
authors.initials: C
authors.lastname: Person
authors.forename: Pablo
authors.initials: P
authors.lastname: Maureira
authors.forename: Henri
authors.initials: H
authors.lastname: Boutley
authors.forename: Gilles
authors.initials: G
authors.lastname: Karcher
authors.forename: Patrick
authors.initials: P
authors.lastname: Lacolley
authors.forename: Véronique
authors.initials: V
authors.lastname: Régnault
authors.forename: Renaud
authors.initials: R
authors.lastname: Fay
authors.forename: Pierre Yves
authors.initials: PY
authors.lastname: Marie
mesh_terms: D000818:Animals; D055424:Cardiac-Gated Imaging Techniques; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology; D006321:Heart / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000502:physiology; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D011719:Pyrazines; D019788:Fluorodeoxyglucose F18; D005947:Glucose; C027696:acipimox
references.citation: Metabolism. 2001 Aug;50(8):945-51
references.pmid: 11474483
references.citation: Mol Imaging Biol. 2009 Jan-Feb;11(1):31-8
references.pmid: 18773246
references.citation: J Nucl Med. 2003 Jun;44(6):877-83
references.pmid: 12791813
references.citation: J Nucl Med. 2003 Oct;44(10):1655-61
references.pmid: 14530482
references.citation: Ann Nucl Med. 1996 Aug;10(3):323-8
references.pmid: 8883708
references.citation: Phys Med Biol. 2009 Apr 21;54(8):2359-76
references.pmid: 19321924
references.citation: J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):308-16
references.pmid: 17643322
references.citation: Eur J Nucl Med. 1994 Mar;21(3):228-31
references.pmid: 8200391
references.citation: Eur J Nucl Med. 1997 Jan;24(1):35-41
references.pmid: 9044874
references.citation: J Nucl Med. 2005 Nov;46(11):1789-95
references.pmid: 16269591
references.citation: J Nucl Med. 2006 Feb;47(2):337-44
references.pmid: 16455641
references.citation: Magn Reson Med. 2008 Feb;59(2):252-9
references.pmid: 18228591
references.citation: Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):545-53
references.pmid: 12589480
references.citation: J Nucl Med. 1995 Nov;36(11):2094-102
references.pmid: 7472605
references.citation: Circulation. 2002 Jul 2;106(1):118-23
references.pmid: 12093780
references.citation: Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):855-97
references.pmid: 15909197
references.citation: J Nucl Med. 2007 Feb;48(2):288-94
references.pmid: 17268027
references.citation: J Nucl Med. 2003 Oct;44(10):1662
references.pmid: 14530483
references.citation: Nucl Med Commun. 1998 Sep;19(9):867-74
references.pmid: 10581593
references.citation: J Nucl Med. 2004 Feb;45(2):176-82
references.pmid: 14960633
references.citation: Circulation. 1993 Aug;88(2):395-404
references.pmid: 8339403
references.citation: J Nucl Med. 2009 Jan;50(1):139-47
references.pmid: 19139188
references.citation: Am J Physiol. 1994 Dec;267(6 Pt 1):E941-6
references.pmid: 7810638
references.citation: Circulation. 2006 Nov 14;114(20):2130-7
references.pmid: 17088453
references.citation: J Nucl Cardiol. 2002 Nov-Dec;9(6):587-93
references.pmid: 12466782
references.citation: J Nucl Med. 1994 Jun;35(6):989-98
references.pmid: 8195886